The global surgical sutures market, also known as the medical stitches industry, is on a steady growth trajectory. Surgical sutures are sterile threads used by surgeons and doctors to close wounds and hold body tissues together after injuries or surgical interventions. These sutures play a crucial role in minimizing infections, accelerating healing, and improving surgical outcomes.
The market size is estimated at USD 4.84 billion in 2024, growing to USD 5.09 billion in 2025, and projected to reach approximately USD 7.96 billion by 2034, advancing at a CAGR of 5.14% between 2025 and 2034.
Download the free sample and get the complete insights and forecasts report on this market @ https://www.towardshealthcare.com/download-sample/5655
Growth is primarily influenced by:
◉ Rising geriatric population leading to higher surgical volumes.
◉ Technological advancements in surgical procedures.
◉ Increasing adoption of minimally invasive surgeries that require specialized sutures.
◉ Innovations in materials, such as biodegradable sutures and antibacterial-coated sutures, that aim to improve patient safety and reduce infection risks.
The global surgical sutures market shows consistent growth over the next decade, supported by higher surgical demand, improved healthcare infrastructure, and the introduction of advanced suture materials. Below is an in-depth look at the market size trajectory:
◉ 2024: USD 4.84 billion
◉ 2025: USD 5.09 billion
◉ 2034 (Projected): USD 7.96 billion
◉ CAGR (2025–2034): 5.14%
This growth indicates that the industry will add more than USD 2.87 billion in value between 2025 and 2034.
◉ From 2024 to 2025, the market is expected to grow by about 5.1%, adding USD 0.25 billion in just one year.
◉ Between 2025 and 2030, the market will maintain steady expansion, crossing the USD 6 billion mark by the end of the decade.
◉ By 2034, the market is projected to touch nearly USD 8 billion, reflecting the sustained demand for surgical procedures worldwide.
◉ In February 2025, the Indian government announced an investment of Rs. 6.5 crore to strengthen the technical textile sector through leading educational institutions.
◉ This initiative is expected to create a highly skilled workforce that will indirectly support the surgical sutures industry, as sutures fall under the technical textile category (medical textiles).
◉ The move highlights how government-driven innovation policies can accelerate the adoption of advanced suture materials, including biodegradable and antibacterial variants.
◉ In March 2024, Mankind Pharma partnered with Healthium Medtech to contest for Apax’s surgical supplies.
◉ Such collaborations demonstrate the rising competition in surgical sutures and medical supplies, with companies seeking to expand their reach through alliances and acquisitions.
◉ This trend indicates a shift toward consolidation, ensuring stronger supply chains and enhanced innovation.
◉ Minimally invasive surgeries (MIS) are becoming the standard in many fields, including gynecology, cardiovascular, and orthopedics.
◉ These procedures require specialized sutures designed for smaller incisions, high precision, and greater maneuverability.
◉ As MIS adoption rises globally, manufacturers are focusing on producing finer, stronger, and bio-compatible sutures.
◉ Manufacturers are actively developing sutures with antibacterial coatings to reduce infection risks.
◉ Biodegradable sutures that naturally dissolve in the body are gaining popularity due to reduced hospital visits and enhanced patient comfort.
◉ This reflects the market’s transition from traditional silk or nylon sutures to high-performance, next-generation materials.
◉ While North America continues to dominate the market, Asia Pacific is showing significant growth potential.
Factors driving this include:
◉ Increasing government spending on healthcare infrastructure.
◉ Rising middle-class population with better access to advanced surgeries.
◉ Expanding medical tourism hubs in India, Thailand, and Singapore.
◉ This shift signals a rebalancing of the global surgical sutures market, with emerging economies playing a more central role.
Artificial Intelligence (AI) is reshaping the surgical sutures industry by streamlining production, enhancing quality control, and supporting advanced surgical applications.
◉ AI-driven automation allows manufacturers to scale production rapidly while maintaining consistent suture quality.
◉ Machine learning algorithms can detect defects in real-time during production, minimizing waste and improving safety.
◉ AI supports the design of sutures with optimized tensile strength, flexibility, and biocompatibility.
◉ Predictive modeling helps in developing biodegradable and antibacterial sutures tailored for patient-specific needs, particularly for minimally invasive surgeries.
◉ In robotic-assisted surgeries, AI-powered systems ensure precise suture placement, reducing the risk of human error.
◉ Sutures designed with AI input are optimized for tiny incisions, improving outcomes in laparoscopy, arthroscopy, and endoscopy.
◉ AI applications in supply chain tracking allow real-time monitoring of raw materials and finished products, reducing delays.
◉ Predictive analytics helps manufacturers estimate demand trends, improve resource allocation, and optimize inventory management.
◉ In 2025, the global rise in aging populations continues to drive the need for surgical interventions. Elderly individuals are more prone to chronic diseases such as cancer, diabetes, and cardiovascular conditions, which require surgical treatment.
◉ Minimally invasive surgeries, such as laparoscopy, are becoming more common, offering benefits like smaller incisions, reduced recovery times, and lower risks. These factors increase the demand for specialized sutures that meet the needs of advanced surgical techniques.
◉ The availability of advanced wound care products (foam dressings, compounded dressings) is reducing the dependency on traditional sutures.
◉ Alternative closure methods such as staples, tissue adhesives, and hemostats are gaining traction, especially in specific surgical segments where they are faster or more cost-effective.
◉ This trend presents a restraint for the surgical sutures market, as it limits demand in certain applications.
◉ The rapid adoption of minimally invasive procedures (MIPs) such as laparoscopy, endoscopy, and arthroscopy is creating new opportunities.
◉ These surgeries use specialized sutures designed for smaller wounds, leading to advantages like reduced scarring, less pain, and quicker recovery.
◉ The growing use of biodegradable and bioabsorbable sutures in these procedures is an opportunity for manufacturers to introduce novel, high-value products that align with market trends.
◉ FDA 510(k) clearance remains mandatory for new suture products. Increasing scrutiny on antibacterial coatings (triclosan, silver, drug-eluting) has lengthened approval timelines but also raised trust in infection-control sutures once approved.
◉ USP (United States Pharmacopeia) standards on suture sizing, tensile strength, and absorption profiles are enforced more strictly, pushing smaller players to invest in advanced quality testing.
◉ Impact: Global majors like Ethicon, Medtronic, and B. Braun with established regulatory teams have a competitive edge, while smaller entrants face higher compliance costs.
◉ The EU Medical Device Regulation (MDR), fully applied since May 2021, requires more rigorous clinical evidence, traceability (UDI), and post-market surveillance.
◉ Sutures, though class II, face stringent demands for biocompatibility data and long-term safety.
Impact:
◉ Some small European manufacturers and Asian exporters reduced presence due to costly compliance.
◉ Larger firms with MDR-ready portfolios (e.g., B. Braun, Corza, Ethicon) consolidated market share.
◉ Hospitals in EU now prefer MDR-compliant brands, which strengthens patient safety but raises procurement costs.
◉ The NMPA tightened requirements on domestic innovation and localized clinical data. For example, Genesis MedTech’s triclosan-coated antibacterial sutures gained NMPA approval in 2023 as the first local brand of its kind.
◉ Impact: Regulations encourage domestic R&D and reduce reliance on imports, favoring Chinese companies with strong R&D pipelines while raising entry barriers for foreign-only portfolios.
◉ Sutures classified as Class C medical devices require CDSCO (Central Drugs Standard Control Organization) approval for both domestic and imported products.
◉ Increasing enforcement of ISO 13485 certification and local clinical evaluation has improved quality benchmarks.
◉ Impact: Local players like Healthium, Dolphin, and Unisur benefit from “Make in India” momentum and streamlined approvals, but imported sutures face stricter pricing oversight and competition from lower-cost domestic sutures.
◉ Japan (PMDA) enforces extensive clinical safety data; this raises time to market but ensures reliability for ophthalmic and cardiovascular sutures.
◉ South Korea (MFDS) aligned with international standards, enabling exports (e.g., Samyang to EU).
◉ ASEAN markets (Thailand, Indonesia) are moving toward harmonization under ASEAN Medical Device Directive (AMDD), improving market access for multinational portfolios.
◉ Impact: Regulatory alignment facilitates regional trade but requires standardized documentation across multiple jurisdictions.
◉ Gulf Cooperation Council (GCC) nations require SFDA (Saudi), DHA (UAE) clearance, which increasingly align with US/EU benchmarks.
◉ South Africa (SAHPRA) enforces ISO/CE equivalency for imported sutures.
◉ Impact: High reliance on imported products creates opportunities for premium international brands, but regulatory delays may slow introduction of novel antibacterial or biodegradable technologies.
◉ Brazil (ANVISA) and Mexico (COFEPRIS) tightened device classification and require detailed clinical evidence.
◉ Impact: Slower approval timelines for innovative sutures but stronger local demand for MDR/FDA-compliant imports. Companies with established regional distributors gain an advantage.
◉ What’s driving growth: high surgical volumes across cardio, ortho, general surgery; rapid adoption of advanced closure (barbed, antibacterial, ophthalmic micro-sutures); strong reimbursement and OR productivity focus.
◉ Regulatory & supply: steady FDA 510(k) flow and abundant domestic/near-shore manufacturing keeps supply resilient. Barbed closure devices (e.g., V-Loc) remain a key differentiator in MIS workflows.
◉ Procedural mix shifting to MIS/ambulatory: barbed sutures speed closure and reduce knot-tying, valued in laparoscopic and robotic cases.
◉ Portfolio breadth from leaders: Ethicon’s antibacterial “Plus” line (MONOCRYL Plus, Coated VICRYL Plus, PDS Plus) and broad polymer set (PROLENE, ETHIBOND, etc.) underpin hospital formulary stickiness.
◉ Cardiothoracic niche innovation: specialized sternal closure/looped wire products (e.g., Valkyrie looped sternotomy sutures) target robustness vs. standard wire for sternotomy closure.
◉ Tech-forward adoption: hospitals and academic centers adopt advanced closure, barbed and antibacterial lines; procurement favors proven infection-control features (e.g., triclosan-coated). (Inference based on cross-listed product availability from Ethicon/Medtronic across North America.)
◉ Why fastest growth: aging populations, rising chronic disease burden, and rapid scale-up of surgical infrastructure and domestic manufacturing.
◉ R&D-led upgrades: landmark innovation with bioabsorbable mechanoelectric (self-electrified) sutures designed to stimulate healing — peer-reviewed and widely reported in 2024.
◉ Antibacterial sutures now local: Genesis MedTech secured NMPA approval (Sept 2023) for triclosan-coated absorbable antibacterial sutures, the first domestic brand, improving SSI prevention options.
◉ Volume & portfolio expansion: strong local players (Healthium, Unisur, Dolphin) plus global brands. Healthium launched TRUMAS in Aug 2023 — a range engineered for challenges in minimal access surgery.
◉ Capital inflow: KKR agreed to acquire Healthium from Apax (₹7,000 crore) via SPV, supporting expansion and global reach.
◉ Materials & capacity hub: South Korea’s Samyang added a European plant but remains an APAC materials/medical-suture powerhouse; regional providers emphasize high-purity polymers and consistent fiber quality for EU/US export.
◉ Procedure growth in ASEAN: expanding private hospitals and surgical tourism broaden demand for advanced absorbables and ophthalmic micro-sutures (inferred from vendor rollouts and capacity expansion feeding global export).
◉ Market character: rigorous EU MDR compliance has favored established portfolios with robust clinical and technical files; ophthalmology and cardio remain innovation hotspots.
◉ New capacity nearby: Samyang Holdings inaugurated a biodegradable suture material plant in Hungary (2023/2024 window), aimed at up to 100,000 km/year suture yarn capacity — strengthening regional supply chains.
◉ Ophthalmic micro-sutures momentum: Corza Medical launched and then expanded its Onatec ophthalmic microsurgical sutures (AAO 2024 launch; portfolio expansion in 2025), targeting retina/cornea precision.
◉ Hospital quality + specialization: strong uptake of advanced absorbables and coated polyesters; B. Braun (Aesculap) maintains a deep local presence with NOVOSYN/MONOSYN families.
◉ Procurement weight on infection control & efficiency: antibacterial sutures and micro-suture portfolios gain traction; UK launch cadence followed AAO introduction for ophthalmic lines.
◉ Tenders favor proven SSI reduction and ergonomic needles: established EU brands dominate; Nordic markets prioritize traceability and MDR documentation, keeping barriers high (supported by the strong presence of EU-compliant portfolios).
Brazil, Mexico, Argentina
◉ Growing surgical capacity & private hospital investments support absorbables and ophthalmic lines; importers lean on multinational portfolios with MDR/FDA documentation to speed approvals. (Inference grounded in global vendor catalog penetration and LATAM distributor networks.)
Saudi Arabia, UAE, Kuwait, South Africa
◉ Premiumization in tertiary centers: GCC imports high-end ophthalmic and antibacterial sutures for cardiac/general surgery; South Africa shows stable demand in public-private mix. (Inference: procurement patterns reflect global brand listings and distributor catalogs.)
Overview: category leader in wound closure with broadest suture catalog and needle geometries.
Flagship lines: VICRYL, MONOCRYL, PDS, PROLENE, ETHIBOND; Plus antibacterial range with triclosan coating for SSI risk reduction.
Strengths: surgeon familiarity, infection-control evidence base, breadth of sizes/needles, global support/training.
Overview: strong in MIS and barbed closure; broad general surgery reach.
Flagship lines: V-Loc barbed suture; Surgipro (polypropylene); plus absorbable/non-absorbable families in wound closure.
Strengths: OR efficiency via barbed tech, large installed robotic/MIS footprint, global service network.
Overview: deep European footprint and MDR-ready dossiers; strong education via Aesculap Academy.
Flagship lines: NOVOSYN (polyglactin 910), MONOSYN (synthetic absorbable monofilament), broad surgical sutures catalog.
Strengths: reliability/handling, EU manufacturing, hospital partnerships.
Overview: scaled wound-closure specialist across Sharpoint and LOOK; building ophthalmic microsuture franchise (Onatec).
Strengths: needle quality/sharpness, breadth in ophthalmic and specialty sets, agile launches.
Overview: not a broad retail suture brand in hospitals, but an OEM suture & fiber producer with customization plus Weck EFx Shield fascial closure system (port closure).
Strengths: OEM vertical integration (materials → finished components), closure accessories in minimally invasive surgery.
Overview: among the top 4 global suture manufacturers (by volume), strong India base with growing exports.
Flagship lines: Trusynth, Truglyde, Monoglyde, PDSynth, Trubarb; TRUMAS™ for minimal access surgeries.
Strengths: cost-effective, broad SKUs, rising innovation cadence; reinforced by KKR acquisition for global scale-up.
Overview: EN ISO/EU MDR/WHO GMP/CE-certified maker with branded (i-Brand) absorbables and specialty sutures; OEM capable.
Strengths: certification stack for exports, value positioning.
Overview: Indian manufacturer with suture kits and hernia mesh portfolio.
Strengths: procedure-specific kits, mesh plus closure ecosystem.
Oct 2024 – Corza Medical introduced Onatec Ophthalmic Microsurgical Sutures at AAO; portfolio expanded in 2025 with ~130 products for ophthalmic use.
May 2024 – KKR to acquire Healthium Medtech from Apax (₹7,000 crore) via an SPV, securing a controlling stake.
Oct 2024 – China research showcased biodegradable, self-electrified sutures that generate micro-current under motion to accelerate healing (Nature Communications; widely covered)
Aug 2023 – Healthium launched TRUMAS (suturing in minimal access surgeries), expanding India-made advanced options.
Jan 2023 – Able Medical Devices launched Valkyrie Looped Sternotomy Sutures for robust sternal closure post open-heart surgery.
Sept 2023 – Genesis MedTech (China) obtained NMPA approval for absorbable antibacterial sutures (triclosan-coated) — first domestic brand.
2023–2024 – Capacity expansion in Europe: Samyang Holdings completed/inaugurated a biodegradable suture materials plant in Hungary (EUR 26.2m), targeting 100,000 km/year yarn by 2025.
◉ Absorbable sutures are made from collagen or synthetic polymers and are widely used in deep tissue closures, especially where removal is difficult.
Growth is being driven by:
◉ Increasing adoption of minimally invasive surgeries.
◉ Patient preference for sutures that dissolve naturally.
◉ Innovations such as antimicrobial coatings and improved tensile strength.
Dominated the market in 2024 and are expected to grow significantly in the forecast period.
◉ Multifilament sutures, often braided, offer high tensile strength and better knot security, making them ideal for complex surgeries like intestinal operations.
◉ With surface coatings, they also reduce friction and infection risks, further enhancing their adoption.
Largest Application Segment in 2024.
◉ Increasing cases of cardiovascular disease have heightened the demand for sutures in bypass surgeries, valve replacements, and vascular procedures.
◉ These surgeries require sutures with high durability, low tissue reactivity, and strong closure properties, ensuring precise performance in high-pressure environments.
Fastest Growing Application Segment.
◉ Rising cases of arthritis, fractures, ligament injuries, and joint replacements are driving demand.
◉ Orthopedic procedures require sutures for bone fixation, tendon repairs, and ligament reconstructions, often in both aging and sports injury populations.
◉ The surge in sports-related soft tissue injuries also adds to the growth in this segment.
How is AI influencing the surgical sutures market?
AI is improving production efficiency, optimizing suture quality, supporting robotics in surgeries, reducing errors, and helping design advanced biodegradable and antibacterial sutures.
2. What challenges are limiting the growth of the surgical sutures market?
The growth is restricted by substitutes like staples, tissue adhesives, and advanced wound care products such as foam dressings, which reduce dependency on traditional sutures.
3. Which recent developments are shaping the surgical sutures industry?
Key developments include Healthium Medtech’s TRUMASTM sutures for minimal access surgeries (India, 2023), Corza Medical’s Onatec ophthalmic sutures (2024), and KKR’s acquisition of Healthium Medtech for Rs 7000 crore (2024).
4. Why is the Asia-Pacific region projected to grow fastest?
APAC growth is driven by a rapidly aging population, rising chronic disease burden in countries like China and India, and increasing adoption of minimally invasive surgical techniques.
5. What opportunities exist for manufacturers in this market?
Manufacturers have opportunities in developing biodegradable and bioabsorbable sutures, antimicrobial-coated materials, and sutures tailored for minimally invasive procedures.
Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/price/5655
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
Web: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
The direct-to-consumer genetic testing market is projected to grow from USD 2.45 billion in 2024 to USD 21.85 billion by… Read More
The global healthcare contact center as a service market was valued at USD 5.86 billion in 2024, grew to USD… Read More
The global medical membrane market was valued at USD 4.26 billion in 2024 and is expected to grow to USD… Read More
The global medical imaging market was valued at USD 41.64 billion in 2024 and is projected to increase to USD… Read More
The global pharma contract research organization (CRO) services market is experiencing significant growth, projected to expand from USD 36.66 billion… Read More
The global Pharma Contract Research Organization (CRO) services market is experiencing significant growth, projected to reach USD 87.03 billion by 2034,… Read More